Stay updated on Amivantamab in Adenoid Cystic Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Amivantamab in Adenoid Cystic Carcinoma Clinical Trial page.

Latest updates to the Amivantamab in Adenoid Cystic Carcinoma Clinical Trial page
- Check5 days agoChange DetectedThe site footer revision changed from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check12 days agoChange DetectedThe study record for amivantamab in recurrent or metastatic adenoid cystic carcinoma is displayed, with trial design, eligibility requirements, outcome measures, participating locations, and study documents and results.SummaryDifference53%

- Check19 days agoChange DetectedThe site footer now shows revision v3.8.0 instead of v3.7.2. The study record continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check33 days agoChange DetectedA notice about NIH’s terminology transition appears above the site navigation, and the site revision changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check47 days agoChange DetectedThe footer revision changes from v3.7.0 to v3.7.1 while the study page continues to display a 403 error.SummaryDifference0.2%

- Check54 days agoChange DetectedThe study page now renders a 403 Forbidden error with a minimal HTML frame and a Home link, indicating restricted access rather than updated study information.SummaryDifference0.5%

Stay in the know with updates to Amivantamab in Adenoid Cystic Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Amivantamab in Adenoid Cystic Carcinoma Clinical Trial page.